Radiotherapy outcomes and risk factors for young patients with head-and-neck squamous cell carcinomas: a matched-pair analysis
Jiadai Zou(Leipzig University), Nils H. Nicolay(University Hospital Leipzig), Henning Schäfer(University Medical Center Freiburg), Thomas Kuhnt(Leipzig University), Alexander Rühle(University of Freiburg), Gunnar Wichmann(Leipzig University of Applied Sciences), Andreas Dietz(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Anca‐L. Grosu(German Cancer Research Center)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|550
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
|JAMA Oncology|2021|369
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
|International Journal of Radiation Oncology*Biology*Physics|2000|218
Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis
|International Journal of Radiation Oncology*Biology*Physics|2003|197